HR Execs on the Move

Alternate Solutions Health Network

www.ashealthnet.com

 
We`re building partnerships and transforming care. Alternate Solutions Health Network was founded in 1999 by David and Tessie Ganzsarto. We collaborate with health systems in joint venture partnerships to create a post-acute care solution, delivering efficient centralized operations and utilizing a best-in-class software platform. Our company has been dedicated, since the very beginning, to transforming the quality of care for both our partners and our patients. Our partnerships are built upon four cornerstones for maximizing quality outcomes and financial performance: Growth, Profitability, Quality Outcomes & Satisfaction, Compliance. By utilizing a centralized operational model we`re able to deliver the highest level ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details
Emily Mowery
Senior Director, Talent Management Profile
Amy Huguenot
Director, Human Resources Business Profile
Stephanie Chillious
Director of Human Resources Operations and Total Rewards Profile

Similar Companies

Genewiz Inc

Genewiz Inc is a South Plainfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Regor Therapeutics

Founded in 2018 by a team of accomplished scientists with a proven track record in drug discovery and executive leadership in top global biopharmaceutical companies, Regor is a pioneering international biotech company with headquarters in Shanghai, China; Boston and San Diego, USA.

Abgent

Abgent is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum`s proprietary product engine, FulcrumSeekâ„¢, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.

Ossium Health

Ossium is building the world`s first bone marrow bank to treat blood cancers, improve organ transplantation, and repair damage from radiation.